Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Biocartis Announces Completion of EUR 30 Million Series E Equity Fundraising

Published: Thursday, November 07, 2013
Last Updated: Thursday, November 07, 2013
Bookmark and Share
Company poised for 2014 commercial launch.

Biocartis has announced the completion of an EUR 30 million Series E equity fundraising. The additional capital will be used to validate Biocartis’ molecular diagnostics platform Idylla™ and its first assay and to continue the development of a range of assays, primarily in the oncology field.

Biocartis is now in pole position to unroll an ambitious commercialization plan in 2014.

This series E round was entirely subscribed by the existing shareholders such as RMM (Rudi Mariën), Debiopharm Diagnostics SA, PMV Tina Fund, Valiance, Johnson & Johnson Development Corporation, Philips, the Wellcome Trust, Petercam, the family offices of Dr. Paul Janssen, Luc Verelst, Rudi Pauwels (founder of Biocartis) and some smaller shareholders, including some employees.

Hilde Windels, CFO of Biocartis, commented: “We believe the successful completion of this fundraise is again a testimony to the quality of Biocartis’ technology, its leading position, its promise to provide the tools for true personalized medicine in an exponentially growing market. Our molecular diagnostics platform Idylla™ truly meets the need of pathologists and key clinicians who recognize the platform as being rapid and easy-to-use, with a high level of standardization. We are delighted that our existing shareholders continue to support Biocartis’ progress, and look forward to putting these resources to work to advance our vision of becoming a fully integrated global diagnostics company.”

Biocartis’ flagship platform Idylla™ and the BRAF cancer assay are expected to be launched in the second half of 2014.

Idylla™ is a compact and scalable molecular diagnostics platform that allows assays to be performed anywhere, anytime without the need for a specialist laboratory environment and trained technicians.

Idylla™ rapidly detects biomarkers in cancer samples, amongst other clinical patient samples, with a much higher sensitivity as compared to standard diagnostic assays and standard sequencing.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Biocartis to Present BRAF Liquid Biopsy Data at ASCO Annual Meeting
BRAF mutations identified by Idylla™ from circulating tumor DNA in plasma associated with treatment response.
Thursday, June 04, 2015
Biocartis and Fast-track Diagnostics Sign Strategic Collaboration
Both Companies aim to develop a range of multiplex tests on the Biocartis Idylla™ system each detecting a range of infectious disease pathogens.
Wednesday, May 27, 2015
Biocartis And Microbiome Collaborate
Collaboration aims to develop rapid and sensitive sepsis test.
Thursday, April 09, 2015
Biocartis Spins Out Life Sciences Multiplex Platform Evalution into Mycartis
Company has combined its Swiss Evalution business unit with Pronota NV to form MyCartis.
Saturday, September 06, 2014
Biocartis Raises EUR 64.5 Million
Investment supports commercial roll-out of Idylla™, Biocartis’ flagship molecular diagnostics system, and the development of the system’s menu of diagnostics tests.
Friday, September 05, 2014
Invetech and Biocartis Announce Biomarker Collaboration
Agreement supporting global development and manufacture of instrument to analyze protein and nucleic acid biomarkers continues multi-year relationship.
Wednesday, April 16, 2014
Biocartis and VIB Join Forces
Company will develop a new CRC assay for MSI biomarker detection.
Monday, December 09, 2013
Biocartis Announces the End of its Alliance with bioMérieux
Agreement for the development and commercialization of the integrated molecular biology system, Idylla™.
Friday, November 29, 2013
Biocartis and Hospital del Mar Join Forces
License agreement to develop diagnostic colon cancer test.
Monday, October 21, 2013
Scientific News
Lung Repair and Regeneration Gene Discovered
New role for hedgehog gene offers better understanding of lung disease.
How Cell Growth Triggers Cell Division
Researchers in Jan Skotheim's lab have discovered a previously unknown mechanism that controls how large cells grow, an insight that could one day provide insight into attacking diseases such as cancer.
Microbe Sleuth
Tanja Bosak examines how life and the Earth evolved in tandem during their early history together.
3 Ways Viruses Have Changed Science for the Better
Viruses are really good at what they do, and we’ve been able to harness their skills to learn about – and potentially improve – human health in several ways.
Restoring Vision with Stem Cells
Age-related macular degeneration (AMRD) could be treated by transplanting photoreceptors produced by the directed differentiation of stem cells, thanks to findings published today by Professor Gilbert Bernier of the University of Montreal and its affiliated Maisonneuve-Rosemont Hospital.
The Age of Humans Controlling Microbes
Engineered bacteria could soon be used to detect environmental toxins, treat diseases, and sustainably produce chemicals and fuels.
Mixed Up Cell Transportation Key Piece of ALS and Dementia Puzzle
Researchers from the University of Toronto are one step closer to solving this incredibly complex puzzle, offering hope for treatment.
Metabolomic Platform Reveals Fundamental Flaw in Common Lab Technology
A new study led by scientists at The Scripps Research Institute (TSRI) shows that a technology used in thousands of laboratories, called gas chromatography mass spectrometry (GC-MS), fundamentally alters the samples it analyzes.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
New Gene Therapy for Vision Loss From a Mitochondrial Disease
NIH-funded study shows success in targeting mitochondrial DNA in mice.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos